Lynch Regenerative Medicine Hires Hee as Chief Scientific Officer
Dr. Hee is an experienced translational scientist and strategic leader, with more than 20 years of industry and research experience. Trained in tissue engineering, with a doctorate from the University of Pennsylvania, Dr. Hee has a keen interest in novel product applications incorporating growth factors, stem cells and biologic scaffolds to drive regenerative healing. With experience in developing products for use in aesthetic medicine and reconstructive surgery, Dr. Hee was identified as an ideal fit for LRM's focus areas in aesthetics and wound care.
'As CSO, Dr. Hee will have responsibility for leading all our teams in Phase I through IV clinical trials, non-clinical research, new product development, quality control, and manufacturing for LRM, LRMA and LRMW. His previous experience with recombinant pure PDGF, and the aesthetic and regenerative medicine fields, make him ideal to work with our current team members to drive further success in these areas,' stated Dr. Samuel Lynch, founder and CEO of LRM.
Most recently, Dr. Hee served as vice president of Device R&D at Allergan Aesthetics, an Abbvie company, with responsibility for device product development, biological research, and biomaterials and drug delivery in support of Allergan Aesthetic's Fillers, Plastic and Regenerative Medicine, and Body Contouring franchises. Prior to that, Dr. Hee served as an associate director of research at BioMimetic Therapeutics, leading the scientific research evaluating recombinant pure platelet-derived growth factor-BB (PDGF-BB) for sports medicine and orthopedic applications.
About Lynch Regenerative Medicine, LLC
Lynch Regenerative Medicine, LLC., is pioneering innovative treatments that aim to revolutionize the $100 billion aesthetics and wound-care markets. Our mission is to leverage our regenerative medicine heritage, and our decades-long commitment to safe and effective regenerative products of the highest quality, to deliver exceptional results for our customers and their patients and thereby redefine the future of aesthetic regenerative medicine. The company was founded in 2023 by Dr. Lynch and is based in Franklin, Tennessee.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 days ago
- Yahoo
Adia Nutrition Partners with CareCredit to Offer up to $25,000 in Affordable Financing for Patient Treatments
Winter Park, Florida--(Newsfile Corp. - July 16, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), an emerging leader in regenerative medicine and personalized wellness solutions, is excited to announce its approval to offer CareCredit's payment plan program to patients, tapping into the $48.35 billion U.S. healthcare finance solutions market (valued in 2023) U.S. Healthcare Finance Solutions Market Size | Companies. This partnership reinforces Adia Nutrition's mission to make advanced treatments more accessible by providing flexible financing options for cutting-edge therapies. CareCredit MastercardTo view an enhanced version of this graphic, please visit: Through CareCredit, Adia Nutrition patients can now finance treatments up to $25,000, making the clinic's more comprehensive and innovative therapies, such as stem cell treatments and regenerative protocols, more attainable. This substantial financing limit empowers patients to invest in their long-term health without financial strain, particularly for Adia's premium offerings. "We are thrilled to collaborate with CareCredit to provide our patients with a financing solution that opens doors to transformative care," said Larry Powalisz, CEO at Adia Nutrition. "With the ability to finance up to $25,000, patients can now access our most advanced treatments with ease, prioritizing their wellness journey." Adia Nutrition has transitioned to CareCredit as its primary financing partner, moving away from its previous provider, Cherry. CareCredit's higher financing capacity of $25,000 offers patients' greater flexibility compared to prior options, streamlining access to Adia's full spectrum of services. Patients interested in exploring Adia Nutrition's treatments with CareCredit financing can visit to learn about eligibility and application. CareCredit's straightforward application process and flexible repayment terms align seamlessly with Adia's patient-centered approach. For investor inquiries or further information, please contact Larry Powalisz at ceo@ or 321-788-0850. About ADIA Nutrition Inc.: Adia Nutrition Inc. is a publicly traded company (OTCQB: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Website: Website: Website: Website: Website: Twitter (X): @ADIA_Nutrition Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events, or otherwise. To view the source version of this press release, please visit Sign in to access your portfolio
Yahoo
7 days ago
- Yahoo
SBC Medical Appoints Dr. Steven R. Cohen as Medical Strategy Advisor to Accelerate Global Expansion
IRVINE, Calif., July 14, 2025--(BUSINESS WIRE)--SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ("SBC Medical"), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced the appointment of Dr. Steven R. Cohen, a globally recognized leader in plastic and craniofacial surgery, as Medical Strategy Advisor. His appointment marks a significant step in the company's strategy to expand its global footprint and enhance its medical excellence. Dr. Cohen is the Founder of Faces+, an advanced aesthetic and reconstructive surgery center in San Diego, California. With over 30 years of clinical experience, he is widely known for his pioneering work in regenerative aesthetics, including the clinical application of fat-derived stem cells, skeletal facial aesthetic surgery, and the integration of artificial intelligence into medical innovation. Dr. Cohen is also the inventor of the internal craniofacial distraction device and LipoCube, both of which have become global standards in the field. Recognized by Newsweek as one of "America's Best Plastic Surgeons," Dr. Cohen has authored numerous scientific publications and textbooks and is a sought-after speaker at international conferences. He is also a Clinical Professor at the University of California, San Diego, and an active member of several global societies, including the American Society of Plastic Surgeons (ASPS). Following its Nasdaq listing in September 2024, SBC Medical has accelerated its global growth initiatives. With Dr. Cohen's participation, the company aims to elevate its medical quality, strengthen brand positioning in international markets, expand academic collaborations, and enhance its physician training programs—further solidifying its presence as a truly global medical group. Message from Yoshiyuki Aikawa, CEO of SBC Medical"It is a great honor to welcome Dr. Steven R. Cohen, a world-class clinician, to our team. His deep expertise and global perspective will play a transformative role in elevating our medical standards, physician education, and brand development. We look forward to his contributions as we enter a new phase of growth." Message from Dr. Steven R. Cohen"I am honored to join SBC Medical, a company that is not only expanding rapidly but also committed to innovation and patient-centered care. SBC Medical's investment in physician education and international collaboration resonates deeply with my own values. I look forward to contributing to the advancement of safer, scientifically grounded, and aesthetically refined regenerative aesthetics on a global scale." About Dr. Steven R. Cohen (Partial Profile) Board-certified in Plastic Surgery and Craniofacial Surgery Founder and Medical Director, Faces+ (San Diego, California) Clinical Professor of Plastic Surgery, University of California, San Diego Inventor of the internal craniofacial distraction device and LipoCube Recognized as one of America's Best Plastic Surgeons by Newsweek Global authority in facial reconstruction, stem cell therapy, and 3D surgical simulation Frequent keynote speaker at international academic societies; author of multiple books and peer-reviewed articles For more information about Dr. Steven R. Cohen, please visit: About SBC Medical SBC Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical consumables procurement (resale), the provision of cosmetic products to franchisee clinics for resale to clinic customers, licensing of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchisee clinic's customer rewards program (customer loyalty point program), and payment tools for the franchisee clinics. For more information, visit View source version on Contacts SBC Medical Group Holdings Incorporated (Asia)Hikaru Fukui / Head of Investor Relations E-mail: ir@ Daisuke Murakami / Public Relations E-mail: pr@ ICR LLC (In the US)Bill Zima / Managing Partner Email:
Yahoo
22-06-2025
- Yahoo
South Korea counts on shipbuilding to ease US tariff woes
Asia's fourth largest economy South Korea is facing gruelling tariffs by US President Donald Trump, but its shipbuilding industry could prove a useful bargaining chip. Already hit by sector levies on steel and car exports, Seoul is laser-focused on negotiations over a 25 percent country-specific tariff that has been suspended until July 8. AFP takes a look at what's going on: - Why shipbuilding? - In the 1970s, South Korea's military leader president Park Chung-hee accelerated the country's heavy industry, designating sectors such as steel and shipbuilding "strategically important" and rolling out state subsidies. At the same time, POSCO was founded -- now one of the world's largest steel producers -- and conglomerate Hyundai built its shipyard in southeastern Ulsan, which started to grow rapidly. European rivals struggled to keep pace. Sweden's Kockums Shipyard filed for bankruptcy in 1987 -- and in a symbolic shift of global shipbuilding power, Hyundai acquired its 140-metre (460-foot) Goliath crane for one dollar. It now towers over southern Ulsan. In the 1990s and 2000s, South Korean shipbuilders such as Hyundai Heavy Industries and Samsung Heavy Industries ramped up investment in research and development, backed by generous government subsidies. The country secured a competitive edge in high-value-added vessels, including LNG carriers, very large crude carriers, and offshore platforms. Now, South Korea ranks as the world's second-largest shipbuilding nation, trailing only behind China. - Is it important? - South Korea's exports hit a record high in 2024, with analysts pointing to shipbuilding as one of the key drivers. The sector accounted for nearly four percent of total exports and grew by almost 20 percent from the previous year -- reaching $25.6 billion. Shipbuilding directly employs around 120,000 workers -- roughly one percent of the country's total workforce -- with indirect employment significantly higher in industrial hubs like Ulsan. Industry data shows so far this year, new orders have exceeded 13 trillion won ($9.4 billion). In March, Hanwha Ocean secured a landmark $1.6 billion contract to build LNG carriers for Taiwan's Evergreen Marine, one of the largest single orders in the sector this year. - Why is it a 'bargaining chip'? - Trump has showed "significant interest in South Korea-US shipbuilding cooperation," said South Korea's trade, industry and energy minister Ahn Duk-geun in April. Like the Europeans, the US shipbuilding industry has lagged behind South Korea and China, and as a result, the sector is seen as a "highly important bargaining chip in trade negotiations," he added. At an APEC finance ministers' meeting in South Korea in May, US Trade Representative Jamieson Greer met Chung Ki-sun, vice chairman of HD Hyundai, the country's largest shipbuilder, before he met Seoul's top officials. "South Korea's shipbuilding and defence industries see a window of opportunity," said Kim Dae-jong, a professor at Sejong University. - How does it help the US? - Greer also met with the CEO of Hanwha Ocean, the first non-American company authorised to carry out a dry-dock maintenance of a US Navy vessel. The move last September was seen as significant as it signalled that Washington sees South Korea, where it already has 28,000 US troops stationed, as a strategic defence hub. With worries growing about China's expanding naval fleet and potential conflict in the Taiwan Strait, the US has begun seeking reliable overseas shipyards to support its operations in the Asia-Pacific region. The global market for ship maintenance, repair, and overhaul is projected to exceed $60 billion annually, according to industry estimates. - Any problems? - Despite multi-billion-dollar contracts, data suggests South Korea's shipbuilding industry is losing ground in the global race. China dominates with South Korea's market share dropping, according to industry data. Demand for eco-friendly vessels is rising, and the government need to overhaul regulations "to support the development of next-generation eco-friendly vessels," Rhee Shin-hyung, a professor at Seoul National University, told AFP. South Korea's woeful demographics also make staffing hard. In Geoje -– home to Samsung Heavy Industries -– the number of residents in their 20s and 30s has nearly halved in recent years. Orders are down in 2025 which hints that "the shipbuilding boom may end sooner than the market anticipated," warned Rhee. Global ship orders between January and April fell by almost half the volume recorded during the same period last year. Shipbuilders have been enjoying a "supercycle" but unfortunately the "peak is expected to be lower and the boom shorter-lived compared to the past," Nam Chul, vice president at HD Hyundai Heavy Industries, told AFP. hs/ceb/ecl
